Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Collegium Pharmaceutical (COLL) Receivables - Other (2024 - 2026)

Collegium Pharmaceutical has reported Receivables - Other over the past 2 years, most recently at $19.8 million for Q4 2025.

For Q4 2025, Receivables - Other fell 20.6% year-over-year to $19.8 million; the TTM value through Dec 2025 reached $19.8 million, down 20.6%, while the annual FY2025 figure was $19.8 million, 20.6% down from the prior year.
Receivables - Other for Q4 2025 was $19.8 million at Collegium Pharmaceutical, down from $25.0 million in the prior quarter.
Over five years, Receivables - Other peaked at $25.0 million in Q4 2024 and troughed at $19.8 million in Q4 2025.